However, the continual failures of clinical trials for neurodegenerative disorders suggest that it is important and necessary to think about new models and strategies, such as motor protein dynein malfunction and mitochondrial dysfunction, both of which are in the spotlight of neurodegeneration therapy, ALS in particular (Eschbach and Dupuis, 2011; Banks and Fisher, 2008; Moreira et al., 2010; Payne and Chinnery, 2015). The gene discussed is IMMT; the disease is amyotrophic lateral sclerosis.